Yakuodo Holdings Competitors and Similar CompaniesClear all

Yakuodo Holdings's competitors and similar companies include GOSH COPENHAGEN, Dromeinter, C.A.Papaellinas and Lavipharm.

	Yakuodo Holdings Yakuodo Holdings (株式会社薬王堂ホールディングス) is a company that operates as a drug store chain.	GOSH COPENHAGEN GOSH COPENHAGEN is a manufacturer and distributor of pharmaceutical and personal care products.	Dromeinter Dromeinter is a distributor of consumer, and pharmaceutical products.	C.A.Papaellinas C.A.Papaellinas is a supplier of pharmaceuticals, cosmetics, and consumer products.	Lavipharm Lavipharm develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products.
Founding Date	Founding Date 1978	Founding Date 1945	Founding Date 1987	Founding Date 1929	Founding Date 1911
Type	Type Public	Type Private	Type Private	Type Private	Type Public
Tags	Tags Retail consumer goods cosmetics pharma	Tags Retail cosmetics health & beauty pharma	Tags Retail consumer goods cosmetics distribution footwear pharma	Tags Retail cosmetics health & beauty pharma	Tags Healthcare Retail consumer goods cosmetics distribution drug development pharma
Locations	Locations Yahaba, JP HQ	Locations Ganløse, DK HQ	Locations Tegucigalpa, HN HQ San Pedro Sula, HN	Locations Latsia, CY HQ	Locations Attica, GR HQ
Employees	Employees 978	Employees 1052% increase	Employees 1221% increase	Employees 2222% increase	Employees 299
Valuation ($)	Valuation ($) 272.2 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 140.1 m
Financial
Revenue (est.)	Revenue (est.) ¥163.8b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €56.4m (FY, 2024)
Cost of goods	Cost of goods ¥128.6b (FY, 2026)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods €26.7m (FY, 2024)
Gross profit	Gross profit ¥35.2b (FY, 2026)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit €32.3m (FY, 2024)
Net income	Net income ¥4b (FY, 2026)	Net income N/A	Net income N/A	Net income N/A	Net income €9m (FY, 2024)